GSK-3

GSK3-IN-4 is a potent glycogen synthase kinase 3 (GSK3) inhibitor, specifically designed to modulate GSK3 activity. This compound has demonstrated significant biological activity relevant to the study of psychiatric disorders, making it a valuable tool for exploring the molecular mechanisms underlying these conditions. GSK3-IN-4's inhibition of GSK3 opens avenues for therapeutic research and the development of novel treatments targeting neurological diseases.

GSK3β-IN-3 is an ATP-competitive inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 0.90 μM. It effectively lowers the phosphorylation levels of tau protein in the BR5706 strain and reduces the accumulation of amyloid-beta (Aβ) aggregates in the CL2006 strain. This compound is essential for research applications focused on Alzheimer's disease (AD), aiding in the understanding of neurodegenerative mechanisms and potential therapeutic strategies.

2B-(SP) is an eIF2B-based substrate specifically designed for glycogen synthase kinase-3 (GSK-3). It exhibits efficient phosphorylation by both GSK-3α and GSK-3β isoforms, making it a valuable tool for studying GSK-3-related signaling pathways and cellular processes. This compound is suitable for research applications involving protein phosphorylation and GSK-3 activity modulation.

CHIR-98023 is a selective and reversible inhibitor of glycogen synthase kinase 3 (GSK3), demonstrating IC50 values of 10 nM for GSK3α and 6.7 nM for GSK3β. This compound enhances insulin signaling and glucose metabolism, making it valuable for research in diabetes and metabolic disorders. Its specificity for GSK3 further supports its potential in elucidating the pathways associated with cell signaling and energy homeostasis.

MJ34 is a potent inhibitor of glycogen synthase kinase-3 beta (GSK-3β) and alpha (GSK-3α), exhibiting IC50 values of 15.4 nM and 31.5 nM, respectively. This compound is critical for studies investigating the role of GSK-3 in cancer biology, including cellular signaling pathways and disease progression. MJ34’s ability to selectively inhibit these kinases makes it a valuable tool for exploring therapeutic strategies in cancer research.

GSK3β-IN-4 is a potent and selective ATP-competitive inhibitor of GSK3β, exhibiting an IC50 of 0.37 nM. This compound also shows activity against GSK3α with an IC50 of 2.75 nM and a selectivity index of 7.4. GSK3β-IN-4 effectively reduces tau phosphorylation at Ser396 and has demonstrated improvements in cognitive deficits in Alzheimer's disease models. It is suitable for research focused on Alzheimer's disease pathophysiology and potential therapeutic interventions.

(Rac)-BRD0705 is a racemic mixture that functions as a selective inhibitor of GSK-3α, exhibiting an IC50 of 66 nM and a Kd of 4.8 μM. This compound demonstrates a notable selectivity for GSK-3α, being eight times more potent than for GSK-3β, which has an IC50 of 515 nM. (Rac)-BRD0705 is relevant for research applications involving acute myeloid leukemia (AML) and other conditions where GSK-3 inhibition may play a critical role in disease mechanisms.

TC-G 24 is a selective glycogen synthase kinase-3β (GSK-3β) inhibitor, exhibiting an IC50 of 17.1 nM. This compound is capable of crossing the blood-brain barrier, making it valuable for research on various neurological and metabolic disorders, including type 2 diabetes mellitus, stroke, and Alzheimer's disease. TC-G 24 offers a useful tool for investigating the therapeutic potential of GSK-3β modulation in relevant disease models.

GSK-3β inhibitor 17 is a potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β). This compound demonstrates a capacity to reduce cisplatin-induced phosphorylation of p65 and the expression of KIM-1 protein and mRNA. Additionally, GSK-3β inhibitor 17 effectively lowers the mRNA levels of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and MCP-1. It exhibits anti-inflammatory properties and holds promise for research into acute kidney injury.

Phospho-Glycogen Synthase Peptide-2 is a specific substrate for glycogen synthase kinase-3 (GSK-3). This peptide facilitates the study of GSK-3 activity and its role in various signaling pathways. It is also suitable for affinity purification of protein-serine kinases, enabling researchers to investigate kinase interactions and functions in cellular processes.

hAChE-IN-5 is a potent inhibitor of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBuChE), exhibiting IC50 values of 0.17 μM for both enzymes. In addition, hAChE-IN-5 demonstrates significant GSK3β inhibition with an IC50 of 0.21 μM. This compound is utilized in research focused on tau protein aggregation and Aβ1-42 self-aggregation, effectively preventing Aβ-dependent neurotoxicity. Furthermore, hAChE-IN-5 can cross the blood-brain barrier, showcasing its potential as a multi-targeted agent in the study of Alzheimer's disease.

GSK-3β inhibitor 20 is a potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β) with an IC50 value of 74.4 nM. This compound is primarily utilized in research applications aimed at understanding the role of GSK-3β in various signaling pathways, including those involved in metabolism, neurodegenerative diseases, and cancer. Its effective inhibition can provide insights into GSK-3β functions and facilitate the development of therapeutic strategies targeting this kinase.

18BIOder is a selective inhibitor of Glycogen Synthase Kinase 3 beta (GSK-3β) with notable neuroprotective properties. This compound has demonstrated efficacy in inhibiting HIV-1, contributing to its potential therapeutic applications in neurodegenerative diseases and HIV research. 18BIOder serves as a valuable tool for understanding the mechanistic pathways involved in GSK-3β modulation and its effects on cell signaling.

GSK-3 Inhibitor 6 is a potent inhibitor of glycogen synthase kinase 3 (GSK-3), displaying IC50 values of 29 nM for GSK-3α and 24 nM for GSK-3β. This compound demonstrates effective central nervous system penetration, making it suitable for neurological research. It is beneficial for studying GSK-3-related pathways in various biological contexts, including cell signaling and neurodegenerative disease models.

JGK-263 is an orally active inhibitor of Glycogen synthase kinase-3β (GSK-3β). It demonstrates neuroprotective properties and has the potential to enhance motor function. This compound is suitable for research applications related to neurological disorders, including amyotrophic lateral sclerosis (ALS).

PIMPC is a novel inhibitor of glycogen synthase kinase 3 (GSK-3), a key regulator in various cellular processes. This compound exhibits antioxidant and metal-chelating properties, contributing to its potential applications in neuroprotection. Research indicates that PIMPC may offer therapeutic benefits in conditions such as Alzheimer's disease, making it a valuable tool for studies focused on neurodegenerative disorders and GSK-3 modulation.

Aloisine RP106 is a potent inhibitor of cyclin-dependent kinases (CDKs) Cdk1/cyclin B and Cdk5/p25, as well as glycogen synthase kinase 3 (GSK3), with IC50 values of 0.70 µM, 1.5 µM, and 0.92 µM, respectively. This compound is valuable for research applications targeting cell cycle regulation and neurodegenerative diseases, where CDK and GSK3 activity contribute to pathological processes. Researchers can utilize Aloisine RP106 to investigate the role of these kinases in various biological contexts including cancer and neurobiology.

PfGSK3/PfPK6-IN-2 is a potent dual inhibitor of PfGSK3 and PfPK6, with IC50 values of 172 nM and 11 nM, respectively. This compound exhibits significant efficacy in the modulation of key signaling pathways in Plasmodium falciparum, making it a valuable tool for malaria research. Its ability to inhibit these targets can aid in the investigation of therapeutic strategies against malaria.

GSK-3β Inhibitor 14 is a benzothiazepinone derivative that acts as a weak inhibitor of glycogen synthase kinase 3 beta (GSK-3β), with an IC50 greater than 100 μM. This compound is utilized in research focusing on GSK-3β-related pathways, potentially contributing to studies in various diseases, including neurodegenerative disorders and metabolic conditions. Its role in modulating GSK-3β activity makes it a valuable tool for elucidating the physiological and pathological functions associated with this important kinase.

ZDWX-25 is a potent dual inhibitor of GSK-3β and DYRK1A, demonstrating an IC50 value of 71 nM for GSK-3β. This compound exhibits significant cytotoxic effects on SH-SY5Y and HL-7702 cell lines, making it a valuable tool for research in neurodegenerative diseases such as Alzheimer's disease. Its inhibitory action on key kinase pathways suggests potential for further exploration in therapeutic applications.

UNC10112785 is a potent inhibitor of serine/threonine kinases, specifically targeting GSK-3β, CDK-2, and CDK-4 with IC50 values of 0.031 μM, 0.016 μM, and 1.99 μM, respectively. This compound exhibits significant biological activity that positions it as a valuable tool in the study of type 2 diabetes. Its ability to modulate key pathways involved in metabolic regulation makes it an essential reagent for researchers investigating therapeutic interventions in diabetic conditions.

BRD1652 is a selective inhibitor of glycogen synthase kinase 3 (GSK-3), a critical regulator in various signaling pathways. This compound has shown potential in modulating GSK-3 activity, making it a valuable tool for investigating the molecular mechanisms underlying emotion-related disorders. Its application can enhance research on neuropsychiatric conditions and therapeutic strategies targeting GSK-3 signaling.

Dihydronarwedine is an inhibitor of glycogen synthase kinase-3β (GSK-3β). At a concentration of 10 μM, it demonstrates a 39% reduction in GSK-3β activity. This compound is useful in research applications related to cellular signaling pathways, neurodegenerative diseases, and cancer therapy, where GSK-3β modulation is of interest.

GSK-3 inhibitor 7 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3), a key regulator in various cellular processes. This compound demonstrates significant activity in modulating GSK-3 signaling pathways, making it a valuable tool for research in neurobiology and related fields. Its application may enhance understanding of GSK-3's role in neurodegenerative diseases and neuronal signaling.

Cazpaullone is a potent glycogen synthase kinase-3 (GSK-3) inhibitor that plays a critical role in cellular signaling pathways. It enhances pancreatic beta cell protection and promotes their replication, making it valuable in diabetes research. Cazpaullone's mechanism of action provides insights into potential therapeutic strategies for diabetes and related metabolic disorders.

GSK-3β inhibitor 25 primarily targets glycogen synthase kinase 3 beta (GSK-3β), demonstrating weak inhibitory activity with an IC50 greater than 100 μM. This compound is utilized in biochemical research to elucidate the role of GSK-3β in various signaling pathways and cellular processes, including metabolism and cell proliferation. Its modest potency may serve as a lead in the development of more selective GSK-3β inhibitors for therapeutic applications.

GSK-3β inhibitor 26 is a potent inhibitor of glycogen synthase kinase 3 beta (GSK-3β), exhibiting an IC50 of 18.23 μM. This compound is instrumental in research focusing on cancer, inflammation, and neurodegenerative diseases, facilitating the exploration of therapeutic pathways and mechanisms associated with GSK-3β modulation.

TD114-2 is a potent and highly selective inhibitor of glycogen synthase kinase-3β (GSK-3β), exhibiting an IC50 value of 48 nM. The compound forms a key hydrogen bond with arginine 141, which contributes to its remarkable specificity for GSK-3β compared to other kinases. TD114-2 is a valuable tool for investigating the role of GSK-3β in various conditions, including diabetes, neurodegenerative diseases, and other disorders linked to GSK-3β dysregulation.

PfGSK3/PfPK6-IN-1 is a selective inhibitor targeting PfGSK3 and PfPK6, with IC50 values of 97 nM and 8 nM, respectively. This compound effectively inhibits the proliferation of blood-stage Plasmodium falciparum 3D7 parasites, making it a valuable tool for malaria research. Additionally, PfGSK3/PfPK6-IN-1 exhibits low cytotoxicity in hepatocyte cultures at concentrations up to 200 nM, with a significant reduction in cell viability observed at 2 μM. Its dual action enhances its potential in studying malaria-related mechanisms and potential therapeutic strategies.

SGK1-IN-8 is a potent inhibitor of SGK1 and GSK3β, exhibiting an IC50 of 0.11 μM against human SGK1 and 3.39 μM against human GSK3β. This compound effectively inhibits the catalytic activities of both SGK1 and GSK3β, leading to a reduction in the phosphorylation of the TAU protein at the Ser214 site. SGK1-IN-8 is utilized in research focused on Alzheimer's disease and related neurodegenerative disorders.